

**CLAIM AMENDMENTS**

Claims 1-22 (Canceled)

23. (previously presented) and (not entered) An isolated polynucleotide ~~have~~having the polynucleotide sequence set forth in Fig. 25 (SEQ ID NO:16), ~~a fragment or a derivative thereof.~~
24. (Currently Amended) An isolated polynucleotide that specifically hybridizes with the polynucleotide of claim 23 under hybridization conditions of about 0.3 M NaCl at temperatures of about 50°C to about 55°C, wherein the encoded protein modulates fertility.
25. (Canceled)
26. (Currently Amended) An isolated polynucleotide that is fully complementary to the polynucleotide sequences of claims 23 or 24.
27. (New) An isolated polynucleotide that specifically hybridizes with the polynucleotide of claim 23 under hybridization conditions of about 0.3 M NaCl at temperatures of about 50°C to about 55°C, wherein the encoded protein modulates ovarian development or ovarian function.
28. (New) An isolated polynucleotide that is fully complementary to the polynucleotide sequence of claim 27.

**Summary of Telephonic Interview**

A telephonic interview was conducted on January 7, 2004 with Examiner Cynthia Wilder, the representative for the Applicants, Melissa W. Acosta, and the representative for the licensee, Fariba Shoarinejad. All the pending claims were discussed in view of the Advisory Action. The Examiner indicated that addition of functional language to claim 24 and the addition of the term “fully” to claim 26 should put the claims in condition for allowance.